RTP Mobile Logo
Data + Perspectives: Investigators Discuss the Effects of Emerging Research on the Care of Patients with Acute Myeloid Leukemia (Webinar Audio Proceedings)
Released May 2021

Proceedings from a live webinar held during the 2021 Highlights of ASH® Virtual Meeting. Featuring perspectives from Drs Alexander Perl and Eunice S Wang. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

    LEARNING OBJECTIVES

    • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine diagnostic testing algorithms for patients with acute myeloid leukemia (AML).
    • Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
    • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and the presentation of appropriate protocol opportunities to patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
    • Develop an understanding of the mechanism of action of, published data with and current clinical role for available IDH1/2 inhibitors for patients with AML and an IDH1 or 2 mutation.
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for AML with other targetable genetic abnormalities to determine the current and potential utility of each in clinical practice.
    • Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with recently approved systemic therapies in the management of AML.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Alexander Perl, MD
    Associate Professor of Medicine
    Perelman School of Medicine
    Member, Leukemia Program
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Syndax Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Onconova Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research (All Monies to Institution): AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Beat AML LLC, Leukemia & Lymphoma Society.

    Eunice S Wang, MD
    Chief, Leukemia Service
    Professor
    Roswell Park Comprehensive Cancer Center
    Buffalo, New York

    Advisory Committee: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, MacroGenics Inc, Novartis, Pfizer Inc, PTC Therapeutics, Stemline Therapeutics Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: DAVA Oncology, Kura Oncology, Pfizer Inc, Stemline Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Astellas.

    Release date: May 2021
    Expiration date: May 2022

Acknowledge and close

Listen to the audio:
(WIFI is recommended for best performance):